Amphetamine Use in the Elderly: A Systematic Review of the Literature

Author(s): Karina Lúcia Moreira Sassi, Natalia Pessoa Rocha, Gabriela Delevati Colpo, Vineeth John, Antonio Lucio Teixeira*.

Journal Name: Current Neuropharmacology

Volume 18 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: To systematically review the literature on the therapeutic use of amphetamine, lisdexamfetamine and methylphenidate in elderly population with and without dementia.

Methods: We conducted two researches on the PubMed, Scopus and Embase using the keywords (“elderly”) AND (“amphetamine” OR “methylphenidate” OR “lisdexamfetamine”) and then (“Alzheimer” OR “dementia”) AND (“amphetamine” OR “methylphenidate” OR “lisdexamfetamine”).

Results: Twenty-nine papers met all the eligibility criteria. The results are encouraging as 81.5% of the studies showed clinical improvement of the investigated condition.

Conclusion: Amphetamines and methylphenidate are probably effective strategies for different conditions in the elderly population. However, further studies are needed to provide more robust evidence on efficacy, dosage and safety for this population.

Keywords: Stimulant, amphetamine, methylphenidate, lisdexamfetamine, dementia, elderly.

[1]
Heal, D.J.; Smith, S.L.; Gosden, J.; Nutt, D.J. Amphetamine, past and present--a pharmacological and clinical perspective. J. Psychopharmacol. (Oxford), 2013, 27(6), 479-496.
[http://dx.doi.org/10.1177/0269881113482532] [PMID: 23539642]
[2]
Rasmussen, N. Amphetamine-type stimulants: The early history of their medical and non-Medical uses. Int. Rev. Neurobiol., 2015, 120, 9-25.
[http://dx.doi.org/10.1016/bs.irn.2015.02.001] [PMID: 26070751]
[3]
Rasmussen, N. America’s first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. Am. J. Public Health, 2008, 98(6), 974-985.
[http://dx.doi.org/10.2105/AJPH.2007.110593] [PMID: 18445805]
[4]
Panenka, W.J.; Procyshyn, R.M.; Lecomte, T.; MacEwan, G.W.; Flynn, S.W.; Honer, W.G.; Barr, A.M. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend., 2013, 129(3), 167-179.
[http://dx.doi.org/10.1016/j.drugalcdep.2012.11.016] [PMID: 23273775]
[5]
Partilla, J.S.; Dempsey, A.G.; Nagpal, A.S.; Blough, B.E.; Baumann, M.H.; Rothman, R.B. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther., 2006, 319(1), 237-246.
[http://dx.doi.org/10.1124/jpet.106.103622] [PMID: 16835371]
[6]
Wilens, T.E. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol., 2008, 28(3)(Suppl. 2), S46-S53.
[http://dx.doi.org/10.1097/JCP.0b013e318173312f] [PMID: 18480677]
[7]
Faraone, S.V. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci. Biobehav. Rev., 2018, 87, 255-270.
[http://dx.doi.org/10.1016/j.neubiorev.2018.02.001] [PMID: 29428394]
[8]
Hodgkins, P.; Shaw, M.; Coghill, D.; Hechtman, L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur. Child Adolesc. Psychiatry, 2012, 21(9), 477-492.
[http://dx.doi.org/10.1007/s00787-012-0286-5] [PMID: 22763750]
[9]
Haber, S.N. Corticostriatal circuitry. Dialogues Clin. Neurosci., 2016, 18(1), 7-21.
[PMID: 27069376]
[10]
Connolly, J.J.; Glessner, J.T.; Elia, J.; Hakonarson, H. ADHD & pharmacotherapy: Past, present and future: A review of the changing landscape of drug therapy for attention deficit hyperactivity disorder. Ther. Innov. Regul. Sci., 2015, 49(5), 632-642.
[http://dx.doi.org/10.1177/2168479015599811] [PMID: 26366330]
[11]
Lammers, G.J. Drugs used in narcolepsy and other hypersomnias. Sleep Med. Clin., 2018, 13(2), 183-189.
[http://dx.doi.org/10.1016/j.jsmc.2018.02.009] [PMID: 29759269]
[12]
Devos, D.; Moreau, C.; Delval, A.; Dujardin, K.; Defebvre, L.; Bordet, R. Methylphenidate: a treatment for Parkinson’s disease? CNS Drugs, 2013, 27(1), 1-14.
[http://dx.doi.org/10.1007/s40263-012-0017-y] [PMID: 23160937]
[13]
Shorer, Z.; Bachner, Y.; Guy, T.; Melzer, I. Effect of single dose methylphenidate on walking and postural stability under single- and dual-task conditions in older adults--a double-blind randomized control trial. J. Gerontol. A Biol. Sci. Med. Sci., 2013, 68(10), 1271-1280.
[http://dx.doi.org/10.1093/gerona/glt035] [PMID: 23580740]
[14]
Nelson, J.C. The role of stimulants in late-life depression. Am. J. Psychiatry, 2015, 172(6), 505-507.
[http://dx.doi.org/10.1176/appi.ajp.2015.15030356] [PMID: 26029800]
[15]
Madhusoodanan, S.; Goia, D. Rapid resolution of depressive symptoms with methylphenidate augmentation of mirtazapine in an elderly depressed hospitalized patient: A case report. Clin. Pract., 2014, 11(3), 283-288.
[http://dx.doi.org/10.2217/cpr.14.32]
[16]
Madhusoodanan, S.; Landinez, J. Methylphenidate augmentation for treatment-resistant depression in an elderly patient with a meningioma. Ann. Longterm Care, 2016, 24(9), 33-36.
[17]
Padala, P.R.; Burke, W.J.; Bhatia, S.C.; Petty, F. Treatment of apathy with methylphenidate. J. Neuropsychiatry Clin. Neurosci., 2007, 19(1), 81-83.
[http://dx.doi.org/10.1176/jnp.2007.19.1.81] [PMID: 17308232]
[18]
Prowler, M.L.; Weiss, D.; Caroff, S.N. Treatment of catatonia with methylphenidate in an elderly patient with depression. Psychosomatics, 2010, 51(1), 74-76.
[http://dx.doi.org/10.1016/S0033-3182(10)70662-9] [PMID: 20118444]
[19]
From the centers for disease control and prevention. Public health and aging: trends in aging--United States and worldwide. JAMA, 2003, 289(11), 1371-1373.
[http://dx.doi.org/10.1001/jama.289.11.1371] [PMID: 12636453]
[20]
Centers for Disease Control and Prevention (CDC). Trends in aging--United states and worldwide. MMWR Morb. Mortal. Wkly. Rep., 2003, 52(6), 101-104, 106.
[PMID: 12645839]
[21]
Kaye, J.A. Healthy brain aging. Arch. Neurol., 2002, 59(11), 1721-1723.
[http://dx.doi.org/10.1001/archneur.59.11.1721] [PMID: 12433258]
[22]
Brown, R.C.; Lockwood, A.H.; Sonawane, B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect., 2005, 113(9), 1250-1256.
[http://dx.doi.org/10.1289/ehp.7567] [PMID: 16140637]
[23]
Niccoli, T.; Partridge, L. Ageing as a risk factor for disease. Curr. Biol., 2012, 22(17), R741-R752.
[http://dx.doi.org/10.1016/j.cub.2012.07.024] [PMID: 22975005]
[24]
Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. Nature, 2016, 539(7628), 180-186.
[http://dx.doi.org/10.1038/nature20411] [PMID: 27830812]
[25]
Peters, R. Ageing and the brain. Postgrad. Med. J., 2006, 82(964), 84-88.
[http://dx.doi.org/10.1136/pgmj.2005.036665] [PMID: 16461469]
[26]
Calipari, E.S.; Ferris, M.J. Amphetamine mechanisms and actions at the dopamine terminal revisited. J. Neurosci., 2013, 33(21), 8923-8925.
[http://dx.doi.org/10.1523/JNEUROSCI.1033-13.2013] [PMID: 23699503]
[27]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 2009, 6(7) e1000097
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[28]
Rohan, K.J.; Rough, J.N.; Evans, M.; Ho, S.Y.; Meyerhoff, J.; Roberts, L.M.; Vacek, P.M. A protocol for the Hamilton rating scale for depression: Item scoring rules, rater training, and outcome accuracy with data on its application in a clinical trial. J. Affect. Disord., 2016, 200, 111-118.
[http://dx.doi.org/10.1016/j.jad.2016.01.051] [PMID: 27130960]
[29]
Lavretsky, H.; Kumar, A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am. J. Geriatr. Psychiatry, 2001, 9(3), 298-303.
[http://dx.doi.org/10.1097/00019442-200108000-00015] [PMID: 11481139]
[30]
Lavretsky, H.; Park, S.; Siddarth, P.; Kumar, A.; Reynolds, C.F., III Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am. J. Geriatr. Psychiatry, 2006, 14(2), 181-185.
[http://dx.doi.org/10.1097/01.JGP.0000192503.10692.9f] [PMID: 16473984]
[31]
Lavretsky, H.; Reinlieb, M.; St Cyr, N.; Siddarth, P.; Ercoli, L.M.; Senturk, D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry, 2015, 172(6), 561-569.
[http://dx.doi.org/10.1176/appi.ajp.2014.14070889] [PMID: 25677354]
[32]
Lavretsky, H.; Kim, M.D.; Kumar, A.; Reynolds, C.F., III Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J. Clin. Psychiatry, 2003, 64(12), 1410-1414.
[http://dx.doi.org/10.4088/JCP.v64n1202] [PMID: 14728100]
[33]
Lazarus, L.W.; Winemiller, D.R.; Lingam, V.R.; Neyman, I.; Hartman, C.; Abassian, M.; Kartan, U.; Groves, L.; Fawcett, J. Efficacy and side effects of methylphenidate for poststroke depression. J. Clin. Psychiatry, 1992, 53(12), 447-449.
[PMID: 1487474]
[34]
Lazarus, L.W.; Moberg, P.J.; Langsley, P.R.; Lingam, V.R. Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch. Phys. Med. Rehabil., 1994, 75(4), 403-406.
[http://dx.doi.org/10.1016/0003-9993(94)90163-5] [PMID: 8172499]
[35]
Devos, D.; Krystkowiak, P.; Clement, F.; Dujardin, K.; Cottencin, O.; Waucquier, N.; Ajebbar, K.; Thielemans, B.; Kroumova, M.; Duhamel, A.; Destée, A.; Bordet, R.; Defebvre, L. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2007, 78(5), 470-475.
[http://dx.doi.org/10.1136/jnnp.2006.100016] [PMID: 17098845]
[36]
Espay, A.J.; Dwivedi, A.K.; Payne, M.; Gaines, L.; Vaughan, J.E.; Maddux, B.N.; Slevin, J.T.; Gartner, M.; Sahay, A.; Revilla, F.J.; Duker, A.P.; Shukla, R. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology, 2011, 76(14), 1256-1262.
[http://dx.doi.org/10.1212/WNL.0b013e3182143537] [PMID: 21464430]
[37]
Turner, D.C.; Robbins, T.W.; Clark, L.; Aron, A.R.; Dowson, J.; Sahakian, B.J. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl.), 2003, 168(4), 455-464.
[http://dx.doi.org/10.1007/s00213-003-1457-3] [PMID: 12734634]
[38]
Sonde, L.; Lökk, J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke - a blinded randomized study. Acta Neurol. Scand., 2007, 115(1), 55-59.
[http://dx.doi.org/10.1111/j.1600-0404.2006.00728.x] [PMID: 17156266]
[39]
Sonde, L.; Nordström, M.; Nilsson, C.G.; Lökk, J.; Viitanen, M. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc. Dis., 2001, 12(3), 253-257.
[http://dx.doi.org/10.1159/000047712] [PMID: 11641592]
[40]
Pickett, P.; Masand, P.; Murray, G.B. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J. Geriatr. Psychiatry Neurol., 1990, 3(3), 146-151.
[PMID: 2282130]
[41]
Wallace, A.E.; Kofoed, L.L.; West, A.N. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am. J. Psychiatry, 1995, 152(6), 929-931.
[http://dx.doi.org/10.1176/ajp.152.6.929] [PMID: 7755127]
[42]
Ayache, D.C.; Junior, R.F. Methylphenidate in a patient with depression and respiratory insufficiency. Int. J. Psychiatry Med., 2001, 31(4), 443-449.
[http://dx.doi.org/10.2190/CXNE-0UFR-7Q04-CQ3M] [PMID: 11949742]
[43]
Padala, P.R.; Padala, K.P.; Lensing, S.Y.; Ramirez, D.; Monga, V.; Bopp, M.M.; Roberson, P.K.; Dennis, R.A.; Petty, F.; Sullivan, D.H.; Burke, W.J. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer’s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am. J. Psychiatry, 2018, 175(2), 159-168.
[http://dx.doi.org/10.1176/appi.ajp.2017.17030316] [PMID: 28945120]
[44]
Padala, P.R.; Burke, W.J.; Shostrom, V.K.; Bhatia, S.C.; Wengel, S.P.; Potter, J.F.; Petty, F. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am. J. Geriatr. Psychiatry, 2010, 18(4), 371-374.
[http://dx.doi.org/10.1097/JGP.0b013e3181cabcf6] [PMID: 20220576]
[45]
Rosenberg, P.B.; Lanctôt, K.L.; Drye, L.T.; Herrmann, N.; Scherer, R.W.; Bachman, D.L.; Mintzer, J.E. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J. Clin. Psychiatry, 2013, 74(8), 810-816.
[http://dx.doi.org/10.4088/JCP.12m08099] [PMID: 24021498]
[46]
Herrmann, N.; Rothenburg, L.S.; Black, S.E.; Ryan, M.; Liu, B.A.; Busto, U.E.; Lanctôt, K.L. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J. Clin. Psychopharmacol., 2008, 28(3), 296-301.
[http://dx.doi.org/10.1097/JCP.0b013e318172b479] [PMID: 18480686]
[47]
Baeyens, H.; Dekoninck, J.; Baeyens, J.P. The experimental use of methylphenidate for hypothermia in patients with lewy body dementia. Eur. Geriatr. Med., 2011, 2, 177-178.
[http://dx.doi.org/10.1016/j.eurger.2011.05.014]
[48]
Goforth, H.W.; Konopka, L.; Primeau, M.; Ruth, A.; O’Donnell, K.; Patel, R.; Poprawski, T.; Shirazi, P.; Rao, M. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin. EEG Neurosci., 2004, 35(2), 108-111.
[http://dx.doi.org/10.1177/155005940403500212] [PMID: 15164821]
[49]
Galynker, I.; Ieronimo, C.; Miner, C.; Rosenblum, J.; Vilkas, N.; Rosenthal, R. Methylphenidate treatment of negative symptoms in patients with dementia. J. Neuropsychiatry Clin. Neurosci., 1997, 9(2), 231-239.
[http://dx.doi.org/10.1176/jnp.9.2.231] [PMID: 9144102]
[50]
Reichman, W.E.; Coyne, A.C.; Amirneni, S.; Molino, B., Jr; Egan, S. Negative symptoms in Alzheimer’s disease. Am. J. Psychiatry, 1996, 153(3), 424-426.
[http://dx.doi.org/10.1176/ajp.153.3.424] [PMID: 8610835]
[51]
Pobee, K.A.; LaPalio, L.R. Anorexia nervosa in the elderly: A multidisciplinary diagnosis. Clin. Gerontol., 1996, 16(3), 3-9.
[http://dx.doi.org/10.1300/J018v16n03_02]
[52]
Lavretsky, H.; Reinlieb, M.; St Cyr, N.; Siddarth, P.; Ercoli, L.M.; Senturk, D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry, 2015, 172(6), 561-569.
[http://dx.doi.org/10.1176/appi.ajp.2014.14070889] [PMID: 25677354]
[53]
Taylor, W.D. Clinical practice. Depression in the elderly. N. Engl. J. Med., 2014, 371(13), 1228-1236.
[http://dx.doi.org/10.1056/NEJMcp1402180] [PMID: 25251617]
[54]
Unützer, J.; Park, M. Older adults with severe, treatment-resistant depression. JAMA, 2012, 308(9), 909-918.
[http://dx.doi.org/10.1001/2012.jama.10690] [PMID: 22948701]
[55]
Kok, R.M.; Reynolds, C.F. III Management of Depression in Older Adults: A Review. JAMA, 2017, 317(20), 2114-2122.
[http://dx.doi.org/10.1001/jama.2017.5706] [PMID: 28535241]
[56]
Shorer, Z.; Bachner, Y.; Guy, T.; Melzer, I. Effect of single dose methylphenidate on walking and postural stability under single- and dual-task conditions in older adults--a double-blind randomized control trial. J. Gerontol. A Biol. Sci. Med. Sci., 2013, 68(10), 1271-1280.
[http://dx.doi.org/10.1093/gerona/glt035] [PMID: 23580740]
[57]
Schweitzer, J.B.; Lee, D.O.; Hanford, R.B.; Zink, C.F.; Ely, T.D.; Tagamets, M.A.; Hoffman, J.M.; Grafton, S.T.; Kilts, C.D. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol. Psychiatry, 2004, 56(8), 597-606.
[http://dx.doi.org/10.1016/j.biopsych.2004.07.011] [PMID: 15476690]
[58]
Soleimani, R.; Kousha, M.; Zarrabi, H.; Tavafzadeh-Haghi, S.M.; Jalali, M.M. The impact of methylphenidate on motor performance in children with both attention deficit hyperactivity disorder and developmental Coordination Disorder: A randomized double-blind crossover clinical trial. Iran. J. Med. Sci., 2017, 42(4), 354-361.
[PMID: 28761201]
[59]
Al-Aama, T. Falls in the elderly: spectrum and prevention. Can. Fam. Phys., 2011, 57(7), 771-776.
[PMID: 21753098]
[60]
Agashivala, N.; Wu, W.K. Effects of potentially inappropriate psychoactive medications on falls in US nursing home residents: analysis of the 2004 National Nursing Home Survey database. Drugs Aging, 2009, 26(10), 853-860.
[http://dx.doi.org/10.2165/11316800-000000000-00000] [PMID: 19761278]
[61]
Fasano, A.; Canning, C.G.; Hausdorff, J.M.; Lord, S.; Rochester, L. Falls in Parkinson’s disease: A complex and evolving picture. Mov. Disord., 2017, 32(11), 1524-1536.
[http://dx.doi.org/10.1002/mds.27195] [PMID: 29067726]
[62]
Grimbergen, Y.A.; Munneke, M.; Bloem, B.R. Falls in Parkinson’s disease. Curr. Opin. Neurol., 2004, 17(4), 405-415.
[http://dx.doi.org/10.1097/01.wco.0000137530.68867.93] [PMID: 15247535]
[63]
Nobis, L.; Husain, M. Apathy in Alzheimer’s disease. Curr. Opin. Behav. Sci., 2018, 22, 7-13.
[http://dx.doi.org/10.1016/j.cobeha.2017.12.007] [PMID: 30123816]
[64]
Guimarães, H.C.; Levy, R.; Teixeira, A.L.; Beato, R.G.; Caramelli, P. Neurobiology of apathy in Alzheimer’s disease. Arq. Neuropsiquiatr., 2008, 66(2B), 436-443.
[http://dx.doi.org/10.1590/S0004-282X2008000300035] [PMID: 18641892]
[65]
Schulz, R.; O’Brien, A.T.; Bookwala, J.; Fleissner, K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist, 1995, 35(6), 771-791.
[http://dx.doi.org/10.1093/geront/35.6.771] [PMID: 8557205]
[66]
Mitrani, V.B.; Czaja, S.J. Family-based therapy for dementia caregivers: clinical observations. Aging Ment. Health, 2000, 4(3), 200-209.
[http://dx.doi.org/10.1080/713649924] [PMID: 18548132]
[67]
Steinkellner, T.; Freissmuth, M.; Sitte, H.H.; Montgomery, T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and D-amphetamine. Biol. Chem., 2011, 392(1-2), 103-115.
[http://dx.doi.org/10.1515/bc.2011.016] [PMID: 21194370]
[68]
North, B.J.; Sinclair, D.A. The intersection between aging and cardiovascular disease. Circ. Res., 2012, 110(8), 1097-1108.
[http://dx.doi.org/10.1161/CIRCRESAHA.111.246876] [PMID: 22499900]
[69]
Indave, B.I.; Sordo, L.; Bravo, M.J.; Sarasa-Renedo, A.; Fernández-Balbuena, S.; De la Fuente, L.; Sonego, M.; Barrio, G. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review. Drug Alcohol Rev., 2018, 37(1), 56-69.
[http://dx.doi.org/10.1111/dar.12559] [PMID: 28485090]
[70]
Westover, A.N.; Halm, E.A. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc. Disord., 2012, 12, 41.
[http://dx.doi.org/10.1186/1471-2261-12-41] [PMID: 22682429]
[71]
Kornfield, R.; Watson, S.; Higashi, A.S.; Conti, R.M.; Dusetzina, S.B.; Garfield, C.F.; Dorsey, E.R.; Huskamp, H.A.; Alexander, G.C. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr. Serv., 2013, 64(4), 339-346.
[http://dx.doi.org/10.1176/appi.ps.201200147] [PMID: 23318985]
[72]
Gurian, B.; Rosowsky, E. Low-dose methylphenidate in the very old. J. Geriatr. Psychiatry Neurol., 1990, 3(3), 152-154.
[PMID: 2282131]
[73]
Berman, S.M.; Kuczenski, R.; McCracken, J.T.; London, E.D. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol. Psychiatry, 2009, 14(2), 123-142.
[http://dx.doi.org/10.1038/mp.2008.90] [PMID: 18698321]


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 2
Year: 2020
Page: [126 - 135]
Pages: 10
DOI: 10.2174/1570159X17666191010093021
Price: $65

Article Metrics

PDF: 59
HTML: 2